An observational study in Preeclampsia, Gestational Hypertension and Gestational Diabetes, sponsored by Umraniye Education and Research Hospital. Recruiting at 1 site in Turkey. Open to female participants aged 18 Years to 39 Years. Per ClinicalTrials.gov, last updated 2024-05-16.
Sponsored by Umraniye Education and Research Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Pre-Eclampsia with a site in Turkey — 11 open to participants now, 11 under way, none of them phase 3. Pre-Eclampsia · Turkey.
Among the 50 studies in Pre-Eclampsia with a site in Turkey, this one is the 20th largest by planned enrollment of the 31 observational ones that give a count, is one of 8 that started in 2023, is one of 31 observational ones, reaches primary completion later than 2 of the 10 other live ones, and was the 31st registered.
918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.
Browse Pre-Eclampsia studies →11 of the 50 studies in Pre-Eclampsia with a site in Turkey are open now. Recruiting first, the newest first:
Muğla Sıtkı Koçman University · Sites in Turkey
Ages 18–45 · Women only · Healthy volunteers
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 18+ · Women only
Samsun University · Sites in Turkey
Ages 18–45 · Women only · Healthy volunteers
Aysegul Kilicli · Sites in Turkey
Ages 19–49 · Women only · Healthy volunteers
Hatice Nur Nefes Pala · Sites in Turkey
Ages 18+ · Women only · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.
This study: 18 Years to 39 Years · female.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 8 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 88 is below the median of 165 across 397 observational studies indexed under Pre-Eclampsia.
Median enrollment 84 across the 19 interventional studies, 96 across the 31 observational. Of the 31 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 50 has an industry lead sponsor. The 10 most frequent:
Umraniye Education and Research Hospital is the lead sponsor of 61 studies on the registry; 12 are open to participants now.
Umraniye Education and Research Hospital has 1 study filed under Pre-Eclampsia — fewer than ten, so there is no comparison to draw.
2 of the studies in Pre-Eclampsia with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07874191Muğla Sıtkı Koçman UniversityRetinal and Choroidal Microcirculation in Preeclampsia: An OCTA Study | 2026-12-29 |
| NCT07745036Samsun UniversityRole of Progesterone Membrane Receptors in the Pathogenesis of Preeclampsia | 2027-01-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 50 studies in Pre-Eclampsia with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Investigation of the relationship between maternal serum vasohibin-1, vasohibin-2, cardiotrophin -1 and endocan concentrations at the 11th and 14th weeks of gestation and adverse perinatal outcomes.
Previous animal model studies in the literature have shown that vasohibin-1 released in endothelial cells inhibits angiogenesis, while vasohibin-2 stimulates angiogenesis. Additionally, immunohistochemical studies have shown that vasohibin-2 plays a role in the cellular fusion of trophoblasts in the placenta to form syncytiotrophoblasts.
Studies in the literature have shown that cardiotrophin-1 is expressed in cardiac myocytes and vascular endothelial cells and stimulates the synthesis and secretion of endothelin-1 in endothelial cells through the gp130 signaling pathway. Since endothelin 1 plays an important role in the regulation of vascular tone, cardiotrophin-1 can be considered to act as an endothelium-derived biological factor, possibly involved in the regulation of vascular tone under normal physiological conditions or secondary to pathological processes.
Studies in the literature have shown that maternal serum endocan levels are higher in pregnant women whose pregnancies were complicated by preeclampsia than in normotensive pregnant women, and that the endocan molecule may be effective in the etiopathogenesis of preeclampsia, especially if it develops early.
In the light of this above-mentioned information, we aim to investigate whether serum vasohibin-1, vasohibin-2, cardiotrophin-1 and endocan concentrations measured during the 11th to 14th weeks of pregnancy can be used to predict preeclampsia, gestational hypertension, fetal growth restriction, preterm birth and gestational diabetes mellitus.
Pregnant women with a singleton pregnancy who are between 11 and 14 weeks of gestation, who do not smoke, and do not have any systemic disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pregnant women who do not have any pregestational disease, who gave a blood sample in the first trimester for the study, who did not develop any pregnancy-related disease during their pregnancy, and who gave birth at term.
Diagnostic Test: first trimester serum diagnostic test
Pregnant women who do not have any pregestational disease and who gave a blood sample in the first trimester for the study and who develop preeclampsia, gestational hypertension, preterm birth, fetal growth restriction, and gestational diabetes mellitus in the later weeks of pregnancy.
Diagnostic Test: first trimester serum diagnostic test
First trimester serum vasohibin-1, vasohibin-2, cardiotropin-1 and endocan concentrations predict adverse perinatal outcomes
Usability of serum vasohibin-1, vasohibin-2, cardiotropin-1 and endocan concentrations in predicting adverse perinatal outcomes
Usability of serum vasohibin-1, vasohibin-2, cardiotropin-1 and endocan concentrations in predicting adverse perinatal outcomes
Time frame: 1 year
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2023 (actual). Primary completion is estimated for Nov 2024, 20 months after the start.
Of 191 non-industry observational studies under Pre-Eclampsia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 56. This study's planned 20 months is below that.
Counting every sponsor, half of 200 studies reached it within 30 months; a quarter within 11 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Umraniye Education and Research Hospital